BALCAO · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · MID CAP
Inotiv, Inc. NOTVQ
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$513.0M
▲ 4.5% vs FY2024
EPS · FY25
$-2.11
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-44.8%
Net margin · FY25
-13.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 513.0M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 13 cents on every revenue dollar this year.
Per share
USD -2.11
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-44.8%
Return on equity, FY2025
ROE
Operating margin-6.0%
Net margin-13.4%
Return on assets-8.8%
Each USD of equity lost 45 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+53.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.2%
+53.4%
+36.6%
+21.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+96.5%
Change, 10 years+129.4%
The share count grew 97% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 771.1M
total assets, end of FY2025
Total assetsUSD 771.1M
EquityUSD 136.0M
CashUSD 21.7M
Gross debtUSD 402.1M
Net debtUSD 380.4M
Current ratio0.35×
Net debt stands at 280% of equity.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.5
0.5
0.6
0.5
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.1
−0.1
−0.3
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
EBITDA $B
·
·
·
·
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
·
Income tax $B
−0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.1
−0.1
−0.1
−0.3
0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
0.0
−0.0
0.0
−0.0
EPS, diluted $
−2.11
−4.19
−4.10
−13.84
0.19
−0.43
−0.08
−0.02
0.10
−0.40
0.07
−0.13
0.09
−0.88
−0.74
−0.55
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−44.8
−49.3
−33.4
−144.8
19.3
−51.2
−7.3
−2.0
11.1
−35.5
10.8
−11.3
8.7
−55.7
18.4
−25.2
Shares out B
0.03
0.03
0.03
0.03
0.02
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
60 of 60
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed